Envo recombinant epitope protein and application thereof
By developing envo recombinant epitope proteins with strong specificity and high sensitivity, the problems of poor specificity and difficulty in early detection of OPA diagnostic methods are solved, and efficient and accurate JSRV detection is achieved, which is suitable for batch detection and population of living sheep Test.
Patent Information
- Application Number
- CN202411027041.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
Smart Images

Figure CN118909055A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of virus detection, and in particular relates to an Envo recombinant epitope protein and an application thereof. Background Art
[0002] Ovine pulmonary adenomatosis (OPA), also known as retrovirus, is an infectious epithelial lung tumor in sheep caused by jaagsiekte sheep retrovirus (JSRV). The clinical manifestations of the disease are dyspnea, coughing and mental depression, and eventually death due to loss of alveolar function and respiratory failure. OPA was first discovered in Africa and then spread to Europe, America and Asia. At present, OPA occurs in major sheep-raising countries in the world. Sheep are most susceptible to infection, with an incidence rate of 2% to 5%. A few goats and European wild argali can also be infected with JSRV, but cattle and other animals are not infected. Sheep-raising areas in my country such as Gansu, Qinghai, Xinjiang and Inner Mongolia are areas with a high incidence of OPA, with a mortality rate close to 100%.
[0003] OPA can be transmitted in two ways: horizontally and vertically. Horizontally, it can be transmitted through the respiratory and digestive tracts, with respiratory infection being the main route. JSRV is excreted from the body by sick sheep through coughing and panting, spread in the air and environment, and transmitted to neighboring sheep through aerosols, while lambs and young sheep can be infected through the digestive tract. JSRV can also be transmitted vertically from ewes with OPA to fetuses through the placenta and milk, causing lambs to suffer from OPA. The incubation period of natural infection ranges from about half a year to 2 years, but the incubation period of artificial infection is generally only 3 to 7 months. OPA is mostly sporadic, and sometimes it can also be endemic, especially in captive sheep flocks. Late winter and early spring are the peak periods of OPA. In recent years, with the transformation of sheep farming to large-scale and barn-feeding, the incidence of the disease has increased significantly, and it often appears with a mixture of typical and atypical characteristics. It is difficult to be discovered clinically, and is often diagnosed after the corresponding lung tissue pathological changes are found after the sheep die or are slaughtered. It seriously threatens the development of the sheep industry and also poses a food safety risk. However, domestic research on the disease is still in the exploratory stage, and the pathogenesis of the disease is not very clear. Therefore, if we want to effectively prevent and control the disease, we urgently need to develop a simple and efficient method for diagnosing the OPA pathogen.
[0004] Since no circulating antibodies or T lymphocyte responses against JSRV can be detected in sheep infected with OPA, the disease cannot be diagnosed by detecting antibodies through serological methods. Therefore, the current diagnosis of OPA mainly detects the pathogen. The methods used are mainly the following: (1) Histopathological detection: Histopathological detection is a detection method visible to the naked eye, involving the collection, fixation, embedding, preparation, staining and microscopic observation of lung tissue. Proliferation changes of alveolar wall cells and bronchial mucosal epithelial cells, development and secretion of mucus by adenoma epithelial cells, leading to cell adhesion and formation of adenoma foci, alveolar cavity space filled with macrophages, severe adenoma foci expansively growing, fusion to form papillary tumor-like structures, etc., can be judged as OPA. On this basis, in situ hybridization and dot hybridization techniques were further developed. This method has good specificity and can effectively determine the pathogen, but it is time-consuming and technically demanding. It can only be performed on lung tissue collected after slaughter, autopsy or death. It cannot be used for early diagnosis and is not suitable for large-scale screening. (2) PCR (polymerase chain reaction) detection: PCR is currently the most commonly used diagnostic test method for OPA, mainly through the detection of JSRV RNA or proviral DNA in samples such as blood and nasal swabs. PCR detection is to design specific primers for the JSRV viral envelope protein gene, the U3 region of the long terminal repeat sequence LTR, etc., reverse transcribe JSRV into cDNA, use a thermal cycler (PCR instrument) for nucleic acid amplification, and observe under ultraviolet light after nucleic acid electrophoresis. If there is a corresponding amplification product band, it can be judged that JSRV infection exists and OPA is confirmed. It includes conventional PCR, nested PCR, fluorescent quantitative PCR, etc. This type of method has good specificity, high sensitivity, and short time, and is suitable for laboratory testing. The main disadvantage is that it is not suitable for large-scale clinical screening. (3) Other methods: Some studies have reported a sandwich ELISA method using rabbit anti-JSRV-SU polyclonal antibody as the capture antibody and anti-JSRV-SU monoclonal antibody as the detection antibody. However, this method has only been seen in research reports and no mature products have been launched on the market. The possible reason is that it has poor specificity and unstable clinical testing.
[0005] Therefore, it is particularly important to develop a reagent or method that can target pathogen structural proteins for large-scale testing of living sheep. Summary of the invention
[0006] In order to improve the performance of JSRV detection reagents, the inventors studied the full-length env protein. Through a large number of experiments, they selected an envo recombinant epitope antigen from a variety of different truncated proteins, which has strong specificity, good repeatability, high sensitivity, and meets the needs of immunodiagnostic reagent development, thereby completing the present invention.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] In a first aspect, the present invention provides an envo recombinant epitope protein, wherein the amino acid sequence of the envo recombinant epitope protein is:
[0009] 1) as shown in SEQ ID NO: 1; or
[0010] 2) A derivative amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence in 1), wherein the derivative amino acid sequence has the activity of the amino acid sequence shown in 1).
[0011] A second aspect provides a polynucleotide, wherein:
[0012] a) encoding the envo recombinant epitope protein according to claim 1;
[0013] b) as shown in SEQ ID NO:2; or
[0014] c) is complementary to a) or b).
[0015] In a third aspect, a polynucleotide construct is provided, wherein the polynucleotide construct contains the polynucleotide as described in the present invention.
[0016] In a fourth aspect, a host cell is provided, wherein the host cell contains the polynucleotide described in the present invention.
[0017] In a fifth aspect, a composition for detecting JSRV is provided, wherein the composition comprises the envo recombinant epitope protein as described in the present invention, wherein the envo recombinant epitope protein is coated on a solid support, or the envo recombinant epitope protein carries a detectable marker.
[0018] In a sixth aspect, a kit is provided, comprising the envo recombinant epitope protein described in the present invention.
[0019] Preferably,
[0020] 1) The Envo recombinant epitope protein is coated on a solid support;
[0021] 2) the envo recombinant epitope protein carries a detectable marker; or
[0022] 3) The envo recombinant epitope protein is not coated on a solid support and does not carry a detectable marker.
[0023] A seventh aspect provides a kit for detecting JSRV, the kit comprising:
[0024] Solid support coated with Envo recombinant epitope protein,
[0025] Rabbit polyclonal antibody against Envo recombinant epitope protein,
[0026] Anti-rabbit monoclonal antibody with detectable label.
[0027] In an eighth aspect, provided is the use of the envo recombinant epitope protein of the present invention in the preparation of a composition for detecting JSRV or a kit for detecting JSRV.
[0028] A ninth aspect provides use of the composition or kit of the present invention in detecting JSRV.
[0029] In a tenth aspect, an ELISA kit for detecting JSRV is provided, the ELISA kit comprising:
[0030] Solid support coated with Envo recombinant epitope protein,
[0031] Rabbit polyclonal antibody against Envo recombinant epitope protein,
[0032] Anti-rabbit monoclonal antibody with detectable label.
[0033] In the eleventh aspect, an ELISA kit for detecting JSRV is provided, the ELISA kit comprising:
[0034] Solid support coated with Envo recombinant epitope protein,
[0035] Rabbit polyclonal antibody against Envo recombinant epitope protein,
[0036] Anti-rabbit monoclonal antibody with detectable label,
[0037] Negative control: rabbit polyclonal antibody prepared by immunizing rabbits with the full-length JSRV gag protein.
[0038] Positive control: rabbit polyclonal antibody prepared by immunizing rabbits with the full-length JSRV env protein.
[0039] In the present invention, the sheep pulmonary adenoma virus genome is composed of 7460 nucleotides, including 4 genes encoding basic viral proteins, namely gag, pro, pol, and env. Among them, gag encodes matrix protein (MA), capsid protein (CA) and nucleocapsid protein (NC); pro encodes aspartate protease (PR), pol encodes reverse transcriptase (RT) and integrase (IN); env encodes surface glycoprotein (SU) and transmembrane protein (TM). The env gene overlaps at the end of the viral genome, and the protein it encodes has a direct carcinogenic effect and can drive cell transformation in vivo and in vitro. Bioinformatics predicted that the env protein contained multiple dominant epitope regions with high antigenicity, which were mainly located at amino acids 54-67, 90-109, 118-165, 179-194, 201-215, 236-250, 273-284, 295-310, 309-332, 335-356, 363-381, 461-476, 540-546, 572-596 and 600-615, which are of great significance for the diagnosis of OPA.
[0040] In the present invention, the quality of env recombinant epitope protein is the most critical factor affecting JSRV immunoassay, so there is a need in the art to continuously improve the performance of env recombinant epitope protein to better enhance and meet the needs of JSRV in vitro detection capabilities. At the same time, since the antigens of viral infectious diseases are often large, it is difficult to express complete antigen proteins in vitro, or even if in vitro expression is achieved, antigen proteins with relatively large molecular weights often cannot be folded correctly, resulting in difficulty in later renaturation, or the antigen activity obtained by renaturation is very poor, which restricts the development of detection reagents.
[0041] To this end, the present invention provides a new env recombinant epitope protein (i.e., envo recombinant epitope protein), which selects the 54-605aa region of the env full-length protein. The recombinant antigen not only covers the dominant antigenic epitope region of the env recombinant epitope protein, but also has a detection ability that is superior to other antigens that are slightly different from the selected region, and at the same time has stronger specificity, better repeatability and higher sensitivity.
[0042] In the present invention, the derived recombinant antigen can have at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity with the amino acid sequence shown in SEQ ID NO:1.
[0043] The percent identity between amino acid (or nucleic acid) sequences can be determined using standard methods known to those skilled in the art. For example, in order to determine the percent identity between two amino acid sequences, the sequences are aligned to achieve the best comparison purpose. The amino acid residues at the corresponding amino acid positions are then compared. Rooms can be introduced in one or both amino acid sequences to achieve the best comparison, and non-homologous sequences can be ignored for the purpose of comparison. When the position in the first sequence is occupied by the same amino acid residue as the amino acid residue at the corresponding position of the second sequence, then at that position, the two sequences are identical. Taking into account the number of rooms introduced for the best comparison and the length of each room, the percent identity between the two sequences is a function of the number of identical positions shared by the two sequences. Sequence comparisons between the two sequences and percent identity and similarity can be determined using a mathematical algorithm.
[0044] The kit of the present invention can be in various forms well known to those skilled in the art, for example, test paper, test box containing various test reagents, microfluidic chip, etc., and the kit can be manufactured according to known standard procedures. For example, the kit of the present invention can be colloidal gold test paper. For example, the kit of the present invention can include a container, a chip, instructions for use, a buffer, an immunoadjuvant and / or other materials, structures and / or reagents required for diagnosis / detection as needed.
[0045] In the present invention, the envo recombinant epitope protein (antigen) of the present invention, when used to prepare a kit or composition, can be, for example, present in a dissolved or dried form in a container, coated on a solid support [for example, a membrane (such as an NC membrane), a plate, beads (such as magnetic beads), microspheres (such as carboxyl microspheres, amino microspheres, chloromethyl microspheres, physically adsorbed microspheres, etc.)], and present in a dissolved or dried form in a chamber of a chip, but the present invention is not limited thereto.
[0046] In the present invention, other reactants required for diagnosis / detection in the kit of the present invention include, but are not limited to, other env antigens other than the envo recombinant epitope protein (antigen) of the present invention, etc. The above other reactants may be present in a conventional manner in the art, for example, in a dissolved or dried form in a container, coated on a solid support, or in a dissolved or dried form in a chamber of a chip, but the present invention is not limited thereto.
[0047] In the present invention, other materials required for detection in the kit of the present invention include but are not limited to materials for sampling, materials for comparison and / or materials for observing the detection process or results.
[0048] In the present invention, other reagents required for detection in the kit of the present invention include but are not limited to buffer, detergent, color developer and / or terminator.
[0049] In the present invention, the envo recombinant epitope protein (antigen) of the present invention is detectably labeled when used to prepare a kit or composition. Any marker and labeling method known to those skilled in the art can be used. Commonly used markers may include enzymes (such as horseradish peroxidase, β-galactosidase, alkaline phosphatase, etc.), radioisotopes (such as 32P or 125I), etc., biotin, digoxin, colloidal metals (such as colloidal gold, etc.), fluorescent dyes (such as fluorescein, rhodamine, Texas Red, etc.), chemiluminescent compounds or bioluminescent compounds (such as dioxetanes, luminol or acridinium, etc.). Any well-known labeling steps in the art can be used, such as covalent coupling of enzymes or biotin groups, iodination, phosphorylation, biotinylation, etc.
[0050] In the present invention, one or more of the other reactants required for detection may also be detectably labeled.
[0051] In the present invention, the present invention includes a method for detecting the presence of JSRV in a subject. For example, the detection method includes: contacting the sample of the subject with a solid support coated with the envo recombinant epitope protein (antigen) of the present invention, and then adding a specific antibody, so that the sample of the subject and the envo recombinant epitope protein (antigen) compete for binding to the specific antibody. Then add a second antibody with a detectable marker, bind it to the specific antibody, and form a second antibody-specific antibody-antigen complex with a detectable marker. The test result is then obtained by measuring the detectable marker. The detection method includes but is not limited to ELISA (enzyme-linked immunosorbent assay), autoradiography, turbidimetry, fluorescence microscopy, direct and indirect enzymatic reactions, radioisotope methods or non-radioisotope methods, etc.
[0052] Preferably, a washing step is further included after the formation of the complex to remove unbound components.
[0053] In the present invention, the sample (sample to be tested) can be selected from serum, chest secretion and nasal secretion of living sheep or goats.
[0054] The present invention also relates to polynucleotides encoding envo recombinant epitope proteins (antigens), for example, for use in producing fusion proteins of recombinant antigens of the present invention. The polynucleotides encoding the envo recombinant epitope proteins (antigens) of the present invention include, but are not limited to: the coding sequence of the envo recombinant epitope protein (antigen) itself; the coding sequence of the envo recombinant epitope protein (antigen) and additional coding sequences; the coding sequence of the envo recombinant epitope protein (antigen) (and optional additional coding sequences) and non-coding sequences, for example, may further include but are not necessarily limited to one or more regulatory nucleic acid sequences, which may be regulated or regulatable promoters, enhancers, other transcriptional regulatory sequences, repressor binding sequences, translational regulatory sequences or any other regulatory nucleic acid sequences.
[0055] The present invention also includes equivalent polynucleotide constructs. It will be appreciated by those skilled in the art that polynucleotide constructs are used to prepare recombinant antigens by recombinant expression, and the polynucleotide constructs comprise nucleic acid molecules encoding recombinant antigens operably linked to expression control sequences, and additionally comprise genetic elements for maintaining and propagating in respective host cells, such as replication origins and / or selectable marker genes.
[0056] In the present invention, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations that may be present in small amounts. Monoclonal antibodies are highly specific for a single antigenic site. Monoclonal antibodies are advantageous because they can be obtained by hybridoma cell line culture and are substantially free from contamination by other immunoglobulins.
[0057] In the present invention, the term "polymonoclonal antibody" refers to an immunoglobulin containing multiple different antigen epitopes. The antibody obtained by immunizing an animal with an antigen, producing an antibody in the animal, and obtaining an animal serum containing the antibody after preliminary purification is a polyclonal antibody. Polyclonal antibodies are mainly present in serum, and the serum obtained from the immunized animal is called antiserum or immune serum. This type of antiserum is a polyclonal antibody against multiple antigenic determinants on the antigen substance, and is a mixture of different types, subclasses and types of immunoglobulins.
[0058] Compared with the prior art, the beneficial effects of the present invention are:
[0059] The present invention optimizes the different interception positions of the env full-length protein, screens out the envo recombinant epitope protein from a variety of different truncated proteins, thereby preparing a kit with strong specificity, good repeatability, high sensitivity, and meeting the development needs of immunodiagnostic reagents. Moreover, the kit of the present invention and PCR technology were used for detection respectively, and the results showed that the conformity rate between the kit of the present invention and the PCR detection results was 98%, which met the use requirements of the in vitro diagnostic kit. Moreover, the detection procedure of the kit of the present invention is a batch operation, which can be suitable for clinical batch detection; it also reduces the operating errors between operators, and the results are more accurate and objective. Furthermore, the operating steps of the kit of the present invention are clear and standardized, and the judgment criteria are objective and accurate, which is suitable for technicians of different knowledge levels.
[0060] The envo recombinant epitope protein of the present invention can be used in an ELISA kit for JSRV detection, can detect the pathogen JSRV of OPA, and cannot detect sheep brucellosis, sheep leukemia, lamb dysentery, sheep enterotoxemia, sheep scurvy, sheep pox, peste des petits ruminants, O-type foot-and-mouth disease, sheep mycoplasma pneumonia and sheep endemic intranasal tumor virus (ENTV); it has good specific binding ability; in addition, the ELISA kit of the present invention that can be used for JSRV detection has good repeatability and high sensitivity.
[0061] On the one hand, the samples that can be detected by the present invention are serum, chest cavity and nasal cavity secretions of living sheep and goats, and sampling is convenient.
[0062] On the other hand, the present invention can not only detect diseased samples of slaughtered, dissected or dead sheep, but can also be used to detect ovine pulmonary adenoma virus in living sheep at different stages (especially early stages). Therefore, it can be used for OPA detection and purification of sheep farm groups, introduction quarantine and OPA epidemiological surveys.
[0063] It can be understood that due to the existence of these properties, the detection cost and use restrictions of JSRV are greatly reduced. In other words, the present invention provides an envo recombinant epitope protein that has been systematically evaluated for in vitro diagnosis and has outstanding comprehensive capabilities. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] In order to more clearly illustrate the technical solution of the present invention, the drawings involved in the description of the embodiments will be briefly introduced below. Obviously, the drawings in the description are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0065] Figure 1 It is the electrophoresis diagram of gagw gene, envw gene and envo gene; among them,
[0066] The first lane in A is lane M, which represents 2000DL DNA Marker; the second lane in A is lane 1, which represents envo gene;
[0067] The first to fourth lanes in B are lanes 1-4, all representing the gagw gene; the fifth lane in B is lane M, representing the 2000DL DNA Marker;
[0068] The first and second lanes in C are lanes 1-2, both representing the envw gene; the fourth lane in C is lane M, representing the 2000DL DNA Marker.
[0069] Figure 2 This is the double enzyme electrophoresis diagram after the connection of gagw gene, envw gene, envo gene and pET-32a; among them,
[0070] Lane M1 in A is 2000DL DNA Marker, lane M2 in A is 15000DL DNA Marker, and lanes 1-2 in A are both pET-32a-envo;
[0071] Lane M1 in B is 2000DL DNA Marker, lane M3 in B is 5000DL DNA Marker, and lanes 1-3 in B are all pET-32a-gagw;
[0072] Lane M2 in C is 15000DL DNA Marker, lane M3 in C is 5000DL DNA Marker, and lanes 1-2 in C are both pET-32a-envw.
[0073] Figure 3 This is the Western blot identification result of Envo recombinant epitope protein. DETAILED DESCRIPTION
[0074] The technical scheme of the present invention is described below in conjunction with the embodiments, but the present invention is not limited to the following embodiments. The experimental methods and detection methods described in each embodiment are conventional methods unless otherwise specified; the reagents and materials described are all commercially available unless otherwise specified.
[0075] Example 1
[0076] Coating antigen preparation
[0077] The coating antigen refers to the envo recombinant epitope protein of the JSRV virus used to coat the ELISA plate. Through a large number of experiments, an envo recombinant epitope protein with strong specificity, good repeatability, high sensitivity, and meeting the development requirements of immunodiagnostic reagents was selected from a variety of different truncated proteins. It was expressed using a prokaryotic expression system, and the specific process is described as follows.
[0078] (1) Primer design and synthesis
[0079] Using the JSRV virus sequence (GenBank ID: AF105220) as a template, three pairs of primers were designed using Oligo7 software (see Table 1).
[0080] Table 1 Primer information
[0081]
[0082] Note: The underlined lines are restriction enzyme cleavage sites.
[0083] (2) Extraction and reverse transcription of JSRV viral RNA
[0084] Select clinical ovine pulmonary adenomas virus positive test samples, and extract ovine pulmonary adenomas virus RNA according to the instructions of the virus genome RNA extraction kit;
[0085] According to the instructions of the reverse transcription kit, reverse transcribe the ovine pulmonary adenoma virus RNA into cDNA.
[0086] (3) Envo, gagw, and envw gene cloning
[0087] Using the above cDNA as template, the corresponding primers (see Table 1) were used to PCR amplify the gagw, envw, and envo genes, and the products were subjected to 1.5% agarose gel electrophoresis to obtain three products with the same size as the expected fragment ( Figure 1 ). Use the method in the instructions of the gel recovery kit to recover the gel.
[0088] (4) Ligation of envo, gagw, envw and pET-32a vector
[0089] The pET-32a plasmid and the gel-recovered products of the three genes envo, gagw, and envw were double-digested with the corresponding enzymes (see Table 1), digested at 37°C for 2 hours, subjected to agarose gel electrophoresis, and recovered by gel excision. The ligated products after ligation with T4 ligase were stored in a refrigerator at 4°C overnight.
[0090] (5) Transformation and identification of pET-32a-envo, pET-32a-gagw, and pET-32a-envw recombinant plasmids
[0091] The above ligation product was transferred into DH5α competent cells, and then spread on LB plates containing Amp+, and incubated in an incubator at 37°C for 12-16 hours. Single clones were selected and placed in 3.0 mL of LB liquid medium containing Amp+, and cultured at 37°C and 220 r / min for 12-16 hours. The liquid culture was subjected to PCR identification of the recombinant plasmid according to the gene amplification procedure, and the recombinant plasmid was extracted for double enzyme digestion identification ( Figure 2 ) and sequencing identification.
[0092] (6) pET-32a-envo, pET-32a-gagw, pET-32a-envw recombinant plasmid expression
[0093] The pET-32a-envo recombinant plasmid, pET-32a-gagw recombinant plasmid, and pET-32a-envw recombinant plasmid identified as positive were transferred into BL21 competent cells, and then spread on LB plates containing Amp+, and incubated in an incubator at 37°C for 12-16 hours. The monoclonal colonies were selected and placed in 3.0 mL of LB liquid medium containing Amp+, and cultured at 37°C and 220 r / min for 12-16 hours. The liquid culture was subjected to PCR identification of the recombinant plasmid according to the gene amplification procedure, and the recombinant plasmid was extracted for double enzyme digestion identification.
[0094] The three identified bacterial cultures were inoculated into 5.0 mL LB liquid culture medium (containing Amp+) and cultured on a shaker at 37°C for about 3 h. The absorbance (OD 600 When the concentration of IPTG was 0.6, IPTG was added to the bacterial solution to make the final concentration reach 0.4 mmol / L, and the expression was induced for 5 h at 37°C shaking incubator (150 r / min), and the protein was purified.
[0095] (7) Western blot identification of envo, gagw, and envw recombinant proteins
[0096] The purified protein was used for protein electrophoresis, and mouse anti-His monoclonal antibody (1:1000) was used as the primary antibody, and goat anti-mouse-HRP (1:10000) antibody was used as the secondary antibody for Western blot identification. Finally, ECL luminescent liquid was used for color development, and the image was collected using a fully automatic chemiluminescence imaging analysis system to obtain three expected recombinant proteins, namely, envo recombinant protein (i.e., envo recombinant epitope protein, comprising the amino acid sequence shown in SEQ ID NO: 1) ( Figure 3 ), gagw recombinant protein (comprising the amino acid sequence shown in SEQ ID NO: 5), and envw recombinant protein (comprising the amino acid sequence shown in SEQ ID NO: 6).
[0097] The above results indicate that three prokaryotic expression vectors capable of effectively expressing envo, gagw, and envw recombinant proteins were successfully constructed: pET-32a-envo (comprising the nucleotide sequence shown in SEQ ID NO: 2), pET-32a-gagw (comprising the nucleotide sequence shown in SEQ ID NO: 4), and pET-32a-envw (comprising the nucleotide sequence shown in SEQ ID NO: 3).
[0098] Example 2
[0099] Preparation of polyclonal antibodies against Envo, Gagw (negative control), and Envw (positive control)
[0100] (1) Purification of three recombinant epitope proteins: envo, gagw, and envw
[0101] Prepare separation gel and concentration gel according to the instructions of the SDS-PAGE denatured acrylamide gel rapid preparation kit. Take 180 μL of 3 samples and add 60 μL of 4× loading buffer, a total of 240 μL. Mix well and put into a water bath at 100℃ and boil for 5 minutes. Use a 10 μL pipette to add the treated sample solution from the top of the gel to the well; put the entire gel into the electrophoresis tank, add buffer, and perform electrophoresis at 80V constant voltage. When the sample moves to the separation gel, adjust the voltage to 100V, and stop the electrophoresis when the bromophenol blue is 2mm away from the edge of the gel; cut the gel that meets the size of the target protein and put it into a clean glass tissue grinder, add 4mL of PBS in an ice bath and grind; collect the grinding liquid, determine the protein concentration, and adjust the concentration to 1.0mg / mL.
[0102] (2) Animal immunization
[0103] Purified recombinant proteins of envo, gagw, and envw were used as antigens to immunize rabbits on days 0, 14, 28, and 35, respectively (Table 2). Blood was collected from the rabbit heart 3 days after the fourth immunization, and after coagulation, the blood was kept at 4°C overnight, centrifuged at 3000 r / min for 4 minutes, and the serum was collected and stored at -80°C for later use.
[0104] Table 2 Immunization schedule
[0105]
[0106]
[0107] (3) Indirect ELISA method for determination of serum titer
[0108] Step 1: Coat the ELISA plate with 5.0 μg / mL of envo recombinant epitope protein;
[0109] Step 2: Add the serum to be tested in a gradient dilution (8.0 μg / mL, 4.0 μg / mL, 2.0 μg / mL, 1.0 μg / mL, 0.5 μg / mL, 0.25 μg / mL, 0.125 μg / mL, 0.0625 μg / mL, 0.03125 μg / mL) to each well, 100 μL / well, and incubate at 37°C for 1 h;
[0110] Step 3: Discard the liquid in the wells, wash the plate 3 times with PBST, 200 μL / well, and finally spin dry;
[0111] Step 4: add goat anti-rabbit IgG-HRP (PBST diluted 1:50000), 100 μL / well, and incubate at 37°C for 1 h;
[0112] Step 5: discard the liquid and wash the plate with PBST, 200 μL / well, repeat the washing 3 times, and finally spin dry;
[0113] Step 6: Add TMB substrate solution, 100 μL / well, seal the plate, and develop color at room temperature in the dark for 15 min;
[0114] Step 7: Add stop solution (2M H2SO4), 100 μL / well, and read OD with a microplate reader. 450 nm value.
[0115] After calculation, the titers of rabbit polyclonal antibodies against envo recombinant epitope protein, negative control serum (rabbit polyclonal antibodies prepared by immunizing rabbits with JSRV gag full-length protein), and positive control (rabbit polyclonal antibodies prepared by immunizing rabbits with JSRV env full-length protein) were 1:12800, 1:6400, and 1:12800, respectively.
[0116] (4) Determination of optimal antigen and antibody working concentrations
[0117] The optimal coating concentration of the protein and the optimal dilution multiple of the positive serum were determined by the square array method. The ELISA plate was coated with 40 μg / mL, 20 μg / mL, 10 μg / mL, 5 μg / mL, 2.5 μg / mL, 1 μg / mL, and 0.5 μg / mL concentrations of envo recombinant epitope protein (antigen) in columns 1 to 7, respectively, at 4°C overnight. The first row was a 100-fold diluted rabbit polyclonal antibody (i.e., primary antibody) against envo recombinant epitope protein, followed by a 2-fold serial dilution. The enzyme-labeled secondary antibody was goat anti-rabbit IgG-HRP (1:50,000). ELISA tests were performed to determine OD 450 After the values were determined, the optimal reaction concentration was screened.
[0118] After calculation, the optimal coating working concentration of envo recombinant protein is 5 μg / mL, and the optimal working concentration of rabbit polyclonal antibody (primary antibody) against envo recombinant epitope protein is 1:500.
[0119] Example 3
[0120] Establishment of JSRV competitive ELISA antigen method (ELISA kit for detecting JSRV)
[0121] (I) Scope of use
[0122] This kit is used to detect whether the sheep and goat samples contain JSRV virus antigens, so as to diagnose whether they are suffering from OPA.
[0123] (II) Types of suitable samples and processing methods
[0124] (1) Nasal swab: A sterile cotton swab is used to collect deep nasal secretions from sheep and goats. Before the test, the cotton swab is shaken with 1.0 mL of PBS to allow the JSRV to dissolve in the liquid.
[0125] (2) Serum: Blood is collected aseptically from sheep and goats, and the serum collected after coagulation and centrifugation is used directly for testing.
[0126] (3) Pleural effusion and other secretions: Centrifuge and obtain the supernatant for testing.
[0127] (III) Materials included in the kit
[0128] (1) Envo recombinant epitope protein (antigen) pre-coated ELISA plate;
[0129] (2) Primary antibody: polyclonal antibody prepared by immunizing rabbits with prokaryotic expression protein of Envo (i.e., rabbit polyclonal antibody against recombinant epitope protein of Envo), diluted 1:500 in PBST;
[0130] (3) Enzyme-labeled secondary antibody: goat anti-rabbit IgG-HRP (i.e., anti-rabbit monoclonal antibody with a detectable marker) diluted 1:50,000 (PBST);
[0131] (4) Substrate: TMB solution;
[0132] (5) Stop solution: 2.0 mol / L H2SO4 solution;
[0133] (6) Positive control: polyclonal antibody prepared by immunizing rabbits with envw prokaryotic expression protein (i.e., polyclonal antibody prepared by immunizing rabbits with JSRVenv full-length protein);
[0134] (7) Negative control: polyclonal antibody prepared by immunizing rabbits with gagw prokaryotic expression protein (i.e., polyclonal antibody prepared by immunizing rabbits with JSRV gag full-length protein);
[0135] (8) Dilution plate;
[0136] (9) Antigen diluent: PBST;
[0137] (10) Sealing film.
[0138] (IV) Operation steps
[0139] (1) Add the sample to be tested to the dilution plate, 100 μL / well, then add the primary antibody, 100 μL / well, mix on a shaker for 10 min, seal the plate with a sealing film, and incubate at 37°C for 1 h;
[0140] (2) Add negative control, positive control, and blank control (PBST) to 2 wells of each ELISA reaction plate, 100 μL / well;
[0141] (3) Add the incubated sample to the ELISA reaction plate, 100 μL / well, seal the plate with a sealing film, and incubate at 37°C for 1 h;
[0142] (4) Wash the plate with PBST, 200 μL / well, wash three times, and spin dry;
[0143] (5) Add enzyme-labeled secondary antibody, 100 μL / well, seal the plate with sealing film, and incubate at 37°C for 1 h;
[0144] (6) Wash the plate with PBST, 200 μL / well, wash three times, and spin dry;
[0145] (7) Add TMB substrate solution, 100 μL / well, seal the plate with a sealing film, and develop the color at room temperature in the dark for 15 min;
[0146] (8) Add stop solution, 100 μL / well;
[0147] (9) Measure OD using an ELISA reader 450 The value of each hole at nm wavelength.
[0148] (V) Result determination
[0149] Blocking rate calculation: PI = (1-P / N) × 100%, where:
[0150] Cut-off value = average PI value of positive control;
[0151] If the PI of the sample to be tested is ≥ the critical value, it is judged as positive, otherwise it is negative.
[0152] Example 4
[0153] Kit related characteristic test
[0154] Three batches of ELISA plates were coated with 5.0 μg / mL of purified envo recombinant protein (i.e., envo recombinant epitope antigen), and the following tests were performed according to the above kit operation steps. During the test, the primary antibody used was a rabbit polyclonal antibody against envo recombinant epitope protein (1:500), and the enzyme-labeled secondary antibody was goat anti-rabbit IgG-HRP (1:50000).
[0155] (1) Specificity test
[0156] The kit of the present invention is used to detect sheep brucellosis, sheep dysentery, sheep enterotoxemia, sheep sudden death, sheep pox, peste des petits ruminants, O-type foot-and-mouth disease, sheep mycoplasma pneumonia and sheep endemic intranasal tumor virus (ENTV), respectively. The detection is repeated 3 times. The results show that the kit of the present invention can specifically detect the pathogen JSRV of OPA, but cannot detect sheep brucellosis, sheep dysentery, lamb dysentery, sheep enterotoxemia, sheep sudden death, sheep pox, peste des petits ruminants, O-type foot-and-mouth disease, sheep mycoplasma pneumonia and sheep endemic intranasal tumor virus (ENTV).
[0157] (2) Sensitivity test
[0158] On the basis of determining the JSRV virus titer in the sample to be tested by real-time fluorescence quantitative PCR, the JSRV sample was diluted at a ratio of 1:10, 1:50, 1:100, and 1:200, and the kit of the present invention was used for detection three times, and the average value was taken to determine the minimum detection amount of JSRV by the kit of the present invention. The minimum detection amount of JSRV by the kit of the present invention is 10 2 copy.
[0159] (3) Repeatability test
[0160] The kit of the present invention is tested by taking two kits from each of the three batches and eight known PCR positive samples. The average value of two replicates is taken and the inter-batch coefficient of variation CV is calculated as (SD / OD 450 nm average value)×100%, the results show that the kit of the present invention has good repeatability.
[0161] (4) Compliance verification test
[0162] 100 nasal swab samples positive for JSRV in epidemiological investigation were taken and respectively tested with the kit of the present invention and compared with PCR detection. The results showed that the coincidence rate between the kit of the present invention and the PCR detection result was 98%, which was a good coincidence rate.
[0163] It should be understood that the disclosed invention is not limited only to the specific method, scheme and material of description, because these all can change.It should also be understood that the terminology used herein is only for the purpose of describing specific embodiment scheme, rather than being intended to limit the scope of the present invention, and the scope of the present invention is only limited to the appended claims.
[0164] Those skilled in the art will also recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also included in the appended claims. It should be noted that the various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments, and the same and similar parts between the various embodiments can be referred to each other.
[0165] Although the optional embodiments of the present invention have been described, those skilled in the art may make additional changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including optional embodiments and all changes and modifications that fall within the scope of the embodiments of the present invention.
[0166] Finally, it should be noted that, in the present invention, the terms "include", "comprises" or any other variants thereof are intended to cover non-exclusive inclusion, so that an article or terminal device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such article or terminal device. In the absence of further restrictions, the elements defined by the sentence "includes a ..." do not exclude the existence of other identical elements in the article or terminal device including the elements.
[0167] The technical solution provided by the present invention is introduced in detail above. Specific examples are used in this article to illustrate the principle and implementation mode of the present invention. At the same time, for those skilled in the art, according to the principle and implementation mode of the present invention, there will be changes in the specific implementation mode and application scope. In summary, the content of this specification should not be understood as limiting the present invention.
Claims
1. An envo recombinant epitope protein, characterized in that: The amino acid sequence of the envo recombinant epitope protein: 1) as shown in SEQ ID NO: 1; or 2) A derivative amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence in 1), wherein the derivative amino acid sequence has the activity of the amino acid sequence shown in 1).
2. A polynucleotide, characterized in that The polynucleotide: a) encoding the envo recombinant epitope protein according to claim 1; b) as shown in SEQ ID NO:2; or c) is complementary to a) or b).
3. A polynucleotide construct, characterized in that The polynucleotide construct contains the polynucleotide according to claim 2.
4. A host cell, characterized in that The host cell contains the polynucleotide according to claim 2.
5. A composition for detecting JSRV, characterized in that The composition comprises the envo recombinant epitope protein as claimed in claim 1, wherein the envo recombinant epitope protein is coated on a solid support, or the envo recombinant epitope protein carries a detectable marker.
6. A kit, characterized in that: The kit comprises the envo recombinant epitope protein according to claim 1.
7. The kit according to claim 6, characterized in that 1) The Envo recombinant epitope protein is coated on a solid support; 2) the envo recombinant epitope protein carries a detectable marker; or 3) The envo recombinant epitope protein is not coated on a solid support and does not carry a detectable marker.
8. A kit for detecting JSRV, characterized in that: The kit comprises: Solid support coated with Envo recombinant epitope protein, Rabbit polyclonal antibody against Envo recombinant epitope protein, Anti-rabbit monoclonal antibody with detectable label.
9. Use of the envo recombinant epitope protein according to claim 1 in the preparation of a composition for detecting JSRV or a kit for detecting JSRV.
10. Use of the composition according to claim 5 or the kit according to claim 8 in detecting JSRV.
